ALRN - Aileron Therapeutics, Inc.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
1.9300
-0.1600 (-7.66%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close2.0900
Open2.1000
Bid1.8300 x 800
Ask1.9500 x 2900
Day's Range1.8100 - 2.1000
52 Week Range0.5200 - 9.1800
Volume185,280
Avg. Volume327,953
Market Cap28.465M
Beta (3Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-2.1270
Earnings DateNov 7, 2018 - Nov 12, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est13.50
Trade prices are not sourced from all markets
  • GlobeNewswire17 days ago

    Aileron Therapeutics Appoints Kathryn Gregory as Chief Business Officer

    Aileron Therapeutics (ALRN), the clinical-stage leader in the field of stabilized cell-permeating peptides to treat cancer and other diseases, today announced that Kathryn Gregory has been named Chief Business Officer (CBO). In this role, Ms. Gregory will head Aileron's business development efforts, including global licensing, collaborations, transactions and alliances. “We are excited to expand our leadership team to include Kathryn Gregory as our Chief Business Officer as Kathryn will play an instrumental role in helping Aileron build value through its business development activities.  Kathryn will oversee our existing collaborations and spearhead the ongoing development of new partnerships,” said Dr. Manuel Aivado, CEO & President of Aileron.

  • ACCESSWIRE2 months ago

    4 Healthcare Stocks Looking To Start February Off Strong

    With the advent of new approaches to medical care, as well as innovative medical technologies coming out of the healthcare industry, news surrounding innovative companies putting their skills to the test in the has worked to attract investors looking for potential opportunities in the space. Premier Health Group (OTC:PHGRF) (CSE:PHGI), Titan Pharmaceuticals Inc (TTNP), Aileron Therapeutics Inc (ALRN), Enochian Biosciences Inc (ENOB) represent four healthcare stocks setting the pace on Friday afternoon. Premier Health Group (OTC:PHGRF) (CSE:PHGI) is a company focused on developing nuanced approaches that combine human skill-based expertise with state-of-the-art technologies used throughout the healthcare industry to create the best-possible care solutions for their growing patient network.

  • Aileron Therapeutics, Inc. (ALRN) Upgraded to Strong Buy: Here's Why
    Zacks2 months ago

    Aileron Therapeutics, Inc. (ALRN) Upgraded to Strong Buy: Here's Why

    Aileron Therapeutics, Inc. (ALRN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

  • GlobeNewswire2 months ago

    Aileron Therapeutics Commences Enrollment in a Phase 2a Expansion Cohort for ALRN-6924 in Combination with Pfizer’s IBRANCE® (palbociclib) in Patients with MDM2-Amplified Cancers

    Aileron Therapeutics (ALRN), the clinical-stage leader in the field of stabilized, cell-permeating peptides to treat cancer and other diseases, today announced that the first patient has been enrolled in a Phase 2a expansion cohort intended to assess preliminary activity and safety of ALRN-6924 in combination with Pfizer’s palbociclib, also known as IBRANCE®, in cancer patients with MDM2-amplified solid tumors. “We are excited to launch this Phase 2a expansion cohort, expanding on our ALRN-6924 clinical trial combination program,” said Vojo Vukovic, MD, PhD, and Chief Medical Officer of Aileron.

  • Could The Aileron Therapeutics, Inc. (NASDAQ:ALRN) Ownership Structure Tell Us Something Useful?
    Simply Wall St.3 months ago

    Could The Aileron Therapeutics, Inc. (NASDAQ:ALRN) Ownership Structure Tell Us Something Useful?

    Every investor in Aileron Therapeutics, Inc. (NASDAQ:ALRN) should be aware of the most powerful shareholder groups. Generally speaking, as a company grows, institutions will increase their ownership. Conversely, insiders often Read More...

  • Aileron Inks Collaboration Deal With Pfizer for Cancer Combo
    Zacks4 months ago

    Aileron Inks Collaboration Deal With Pfizer for Cancer Combo

    Aileron Therapeutics (ALRN) signs a clinical trial collaboration contract with Pfizer to study the combo of Aileron's ALRN-6924 and Pfizer's Ibrance for treating MDM2-amplified cancers. Stock rises.

  • GlobeNewswire4 months ago

    Aileron Enters Clinical Trial Collaboration with Pfizer to Evaluate ALRN-6924 in Combination with IBRANCE® (palbociclib) in MDM2-Amplified Cancers

    Aileron Therapeutics (ALRN), the clinical-stage leader in the field of stabilized, cell-permeating peptides to treat cancer and other diseases, today announced that it has entered into a clinical trial collaboration with Pfizer to evaluate the combination of Aileron’s ALRN-6924 and Pfizer’s palbociclib, also known as IBRANCE®, in MDM2-amplified cancers.  Overexpression of MDM2 in cancer is typically a driver of tumor proliferation.  Aileron expects this Phase 1B trial to start enrolling patients with solid tumors in the first quarter of 2019. ALRN-6924 is a first-in-class, stabilized cell-permeating peptide that mimics the p53 tumor suppressor protein to disrupt the interaction with both its endogenous inhibitors, MDMX and MDM2.  For p53 wild-type tumors, ALRN-6924 can restore p53-dependent tumor suppression.  Palbociclib is an oral inhibitor of cell cycle check-point regulators CDK4/6.  The MDM2 and CDK4 genes are located on chromosome 12 in close proximity to one-another, with CDK4 very frequently co-amplified in the MDM2-amplification-positive patients to be enrolled in this trial.  This co-amplification further suggests a potential patient benefit from combining the MDM2/MDMX-inhibitor ALRN-6924 with the CDK4/6-inhibitor palbociclib1.

  • GlobeNewswire4 months ago

    Recent Analysis Shows Arcimoto, ADOMANI, Lipocine, Aileron Therapeutics, Allena Pharmaceuticals, and Perma-Fix Environmental Services Market Influences — Renewed Outlook, Key Drivers of Growth

    NEW YORK, Nov. 19, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.

  • GlobeNewswire4 months ago

    Aileron Therapeutics Appoints Vojislav Vukovic, MD, PhD, as Chief Medical Officer

    Aileron Therapeutics (ALRN), the clinical stage leader in the field of stabilized, cell-permeating peptides to treat cancer and other diseases, today announced that Vojislav (Vojo) Vukovic, MD, PhD, has been named Chief Medical Officer (CMO). In addition, the Company announced the promotion of Allen Annis, PhD, to Senior Vice President of Research.

  • GlobeNewswire5 months ago

    Aileron Therapeutics Announces Clinical Trial Collaboration with Dana-Farber/Boston Children’s Cancer and Blood Disorders Center

    Investigator-Initiated Phase 1Trial of the Dual MDM2/MDMX Inhibitor ALRN-6924 in Pediatric Cancer WATERTOWN, Mass., Nov. 01, 2018 -- Aileron Therapeutics (NASDAQ:ALRN), the.

  • GlobeNewswire5 months ago

    Aileron Therapeutics to Report Third Quarter 2018 Financial Results on November 7, 2018

    Aileron Therapeutics (ALRN), the clinical stage leader in the field of stabilized, cell-permeable peptides to treat cancer and other diseases, today announced that the Company will report financial results for its third quarter ended September 30, 2018 on Wednesday, November 7, 2018 after the close of the market. Aileron is a clinical-stage biopharmaceutical company advancing a proprietary platform of cell-permeable alpha-helical peptides that address the most important intracellular targets in oncology and other therapeutic areas. For more information, visit www.aileronrx.com, and for more information about our clinical trials please visit www.clinicaltrials.gov.